Axel Schulz has been involved in a broad range of EC and German competition law matters.

During his work on merger control under both EU and German law he has dealt with collective dominance and countervailing buyer power, as well as structural links issues in industries including paper and pulp, aluminum, electricity generation and distribution and pharmaceuticals. His recent deals include cases M.4418 — Nycomed/Altana (pharmaceuticals), M.3435 — Lyondell/Millennium (base and specialty chemicals), M.3179 — Sapa/Remy Claeys (aluminium extrusion) and M.2499 Norske Skog/Haindl (newsprint and magazine paper — Phase II investigation).

Mr. Schulz has particular proficiency in the pharmaceutical industry, where he advises on competition law issues in the fields of distribution, co-marketing, licensing and other kinds of vertical and horizontal cooperation agreements. He represented GSK in a number of cases before the European Courts in Luxembourg, including case T-168/01 (GSK Spain — dual pricing), case C-501/06 (GSK Spain — appeal of case T-168/01 — pending), case C-53/03 (Syfait) where he also assisted in proceedings before the Hellenic Competition Committee and joined cases C-468/06 to C-478/06 (rerun of Syfait — pending).

In addition to pharmaceuticals, Mr. Schulz has been involved in a number of important competition cases before the European Courts, including cases T-65/98 and C-552/03 — Van den Bergh Foods v. Commission (ice cream freezer exclusivity), case T-113/07 — Toshiba v. Commission (appeal of GIS cartel decision — pending), case T-21/05 — Halcor v. Commission (appeal of plumbing tube cartel decision — pending).

He regularly advises companies on cartel investigations and has implemented many antitrust compliance programs for multinational companies.

Bars and Courts
Munich Bar, 1998
Brussels Bar (E list), 2002

Education
LLM, European Law, College of Europe, Bruges, 1999
Law Degree, University of Konstanz, 1996
Diploma, University of Lyon, 1994

Publications
Axel Schulz frequently publishes articles and speaks on various EU law matters, including the following:
Co-author, Chapter on "Recent developments in relation to parallel trade in the European pharmaceuticals sector," Biotechnology and Life Sciences Sector—– Strategies for Growth, Survival and Patent Protection, Financier Worldwide, January 2010
Co-author, "Who is the Predator (2)? The French Competition Council's GSK Predation Decision is Overruled," Competition Law Insight, July 1, 2008
Co-author, "French Competition Council vs. GSK France: who is the predator?," Competition Law Insight, June 2007
Chapter on "Vertical Mergers" for "EC Competition Law — A Critical Assessment," edited by Prof. Amato and Prof. Ehlermann, Hart Publishing, May 2007
European Editor (from January to December 2007), Lloyd's Law Report: Pharma
Presentation, recent competition law developments in the pharmaceutical sector, Biotech Conference, London, 5 December 2006
Co-author, "Special status of IP in the pharmaceutical industry," BNA International, May 2006
Module on "Competition law in the food industry" (part of a ten-module training course "Food Law and Regulation"), Informa, June 2006
Module on "Marketing & Distribution in the Pharmaceutical industry" (part of a ten-module training course "Pharmaceutical Law and Practice"), Informa, December 2005
Co-author, "Parallel trade in Europe — the tide is turning," Pharmaceutical Law Insight, December 2005
Co-Author, Module on "Competition law in the pharmaceutical industry" (part of a ten-module training course "Pharmaceutical Law and Practice"), Informa, November 2005
Chaired panel discussion on merger control developments at Maastricht University, June 2004
"Case note on the Bayer/Adalat judgment," European Law Reporter, 2004
"Case note on Van den Bergh Foods v. Commission," European Law Reporter, 2003

Languages
English
French
German
Italian

Citizenship
Germany